Eli Lilly expanded its China drug-sourcing strategy by signing a discovery-stage collaboration with Beijing-based InnoCare Pharma. The partnership is structured around up to five undisclosed targets, with Lilly gaining rights to develop and commercialize resulting candidates. Terms include $100 million in upfront and near-term payments and as much as $3.25 billion in development and commercial milestones, plus royalties. InnoCare’s role centers on using its discovery platform to identify and advance candidate compounds for later-stage selection by Lilly. The move reinforces that multinational pharma remains active in China for oncology and autoimmune innovation, using large milestone-backed discovery arrangements to manage scientific uncertainty while maintaining fast option value on multiple targets.